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INTRODUCTION
HIV/AIDS figures among the top 10 diseases that 
affect global health and malnutrition represents the 
main risk factor that could affect human health(16). 
Intense CD4+ T lymphocytes depletion, enterocyte 
apoptosis, epithelial tight junction disruption and 
lymphoid cell infiltration occurs in the gastrointestinal 
tract of HIV/AIDS patients. Thus, HIV infection can 
be considered a disease of the gastrointestinal tract, 
given its involvement and importance since the very 
beginning of this disease(4).
Diarrhea is a major and frequent clinical manifes-
tation of HIV infection in the tropics, often leading to 
malabsorption and significant impairment of nutri-
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tional status, quality of life and survival. In addition, 
little is known about the impact of  this process on 
antiretroviral drugs absorption. Although the evi-
dence demonstrates that malnutrition represents an 
independent risk factor for death(21, 23, 30), one can say 
that there is a shortage of therapeutic resources and 
specific formulas for nutritional support for patients 
with HIV/AIDS(20).
Among few existing options, glutamine stands 
out. There is now increasing evidence to recommend 
glutamine supplementation to patients with cancer, 
hematologic diseases and the critically ill. This ami-
no acid, being a precursor of nucleotides synthesis, 
has great significance for rapidly dividing cells like 
occurs in the gut and in the immune system. So, it is 
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reasonable to assume that its replacement is required when 
the endogenous production is not sufficient. The major site 
of glutamine release is the muscle and clinical conditions with 
significant muscle mass decrease could be an indication for 
exogenous replacement of this amino acid(33).
Untreated HIV infection is characterized by early loss of 
structural proteins of lean body mass and, more precisely, of 
body cell mass(30). Therefore, we anticipated that glutamine 
supplementation should also be beneficial for HIV infec-
ted patients, especially those with diarrhea or weight loss. 
Alanyl-glutamine (AG) is replacing glutamine for clinical 
use due to its superior physicochemical solubility and more 
favorable thermal stability in acid medium(9). This informa-
tion enables us to propose this clinical trial to investigate the 
effect of AG supplementation on intestinal permeability and 
absorption in patients with HIV/AIDS in the era of highly 
active antiretroviral therapy (HAART).
METHODS
Study design and ethics
This is a prospective, double-blind randomized place-
bo-controlled trial. Study protocol and informed consent 
were approved by Ethical Committee of Hospital São José 
de Doenças Infecciosas, Fortaleza, CE, Brazil.
Selection and enrollment of participants 
Fifty one HIV positive adults outpatients treated at 
Hospital São José de Doenças Infecciosas, in Fortaleza, CE, 
northeast of Brazil, were invited to participate in the trial as 
they attended for their routine medical appointment. Those 
presenting one or more of  the following conditions were 
excluded: severe dehydration, serious systemic diseases such 
tuberculosis, histoplasmosis, malignancies, active pneumo-
nia, meningitis, sepsis, receiving parenteral nutrition, renal, 
cardiac or hepatic impairment, pregnancy, inability to receive 
food and/or oral medications and unable to give informed 
consent. Three patients did not agree to participate for fear 
that the home visit to receive the medication could identify 
their status as HIV positive and two others were afraid to 
participate in a clinical research. So, 46 subjects were enrolled 
in the trial.
Intervention regimen and study duration
Patients were allocated into two blinded groups by re-
stricted randomization by use of random permuted blocks 
of adequate lengths and follow the protocol summarized in 
Figure 1. AG group was randomized to receive 10 days of an 
oral solution of 50 mL of orange juice enriched with 24 g of 
alanyl-glutamine (Rexim S.A., Degussa Group, Courbevoie, 
France). Glycine (GLY) group was randomized to receive as 
placebo, the same volume of an oral solution of orange juice 
enriched with 25 g of GLY (Spectrum Chemical, Gardena, 
CA) for 10 days, with the same nitrogen concentration, 
appearance and taste of  the solution enriched with AG. 
Treatment intake were directly observed and registered by 
home visitors.
After enrollment, anthropometric measures, complete 
blood count, blood biochemistry, CD4 and HIV viral load 
were performed and patients were scheduled to perform the 
intestinal permeability test and to begin the proposed treat-
ment. Those procedures were performed again 1 day after 
the end of treatment with AG or GLY (day 11).
Intestinal permeability test
After overnight fast and emptying the bladder, each 
enrolled subject ingested a solution containing 5 g of  lact-
ulose (Duphar Laboratories, Southampton, UK) and 1 g of 
mannitol (Henrifarma Produtos Químicos e Farmacêuticos 
Ltda, São Paulo, Brazil) dissolved in 20 mL of water. Urine 
was collected during the next 5 hours after administration 
of  the double sugar solution. Then, the total volume was 
recorded, and an aliquot of  5 mL preserved with chlorhex-
idine (0.236 mg/mL of  urine; Sigma Chemical, St Louis, 
MO, USA) was storage at -20oC for sugar analysis. The 
lactulose and mannitol concentrations were measured by 
HPLC (high performance liquid chromatography) as pre-
viously described(1).
Adverse events and serious adverse events 
monitoring
Adverse events (AE) and serious adverse events (SAE) 
were monitored daily by study staff. An AE was defined 
as any untoward medical occurrence that may arise during 
FIGURE 1. Flow diagram for study protocol
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administration of the AG or placebo GLY and that may or 
may not have a causal relationship with the study agent. A 
SAE was defined as any adverse experience occurring that 
resulted in any of the following outcomes: death, life threat, 
requirement for inpatient hospitalization, persistent or signif-
icant disability or incapacity, or an important medical event. 
All AE and SAE were recorded, reviewed by qualified staff, 
and reported to Ethics Committee.
Statistics
The lactulose/mannitol ratio was selected as the primary 
outcome variable to calculate the sample size because it was 
objective data and because it reflected overall intestinal bar-
rier disruption. On the basis of data from preliminary studies 
(lactulose/mannitol ratio = 0.0146 ± 0.0036) we calculated 
that a sample size of  21 patients in both the control and 
the experimental groups would give 90% power to detect a 
reduction of 30% or more in lactulose/mannitol ratios at a 
significance level of P = 0.05(1).
Statistical analysis was performed using de Statistical 
Package for Social Sciences (version 11.5, SPSS Inc., Chi-
cago, IL, USA). Lactulose and mannitol results were log 
transformed before submission for statistical analysis. To 
assess the homogeneity of  the study groups Student t test 
and c2 and Fisher exact test were used. To evaluate changes 
after nutritional supplementation paired Student t test was 
used. Values were considered statistically significant when 
P≤0.05.
RESULTS
According to the Epidemiological Surveillance Unit 
of  Hospital São José de Doenças Infecciosas, 624 HIV 
infected adults (406 male; 218 female) were under medi-
cal attention at this hospital at the baseline. Of  these 624 
patients, 51 were invited while attended at the hospital for 
routine medical consultation and 46 agreed to participate 
in the clinical study. After blinded randomization, 22 were 
allocated to receive AG and 24 to receive GLY (placebo). 
In AG group five patients discontinued participation: two 
by personal decision; one due to diarrhea and fever; one 
due to dizziness, nausea and vomiting; and another one 
was hospitalized as a result of  head injury in motorcycle 
accident. In this group, therefore, 17 patients completed the 
clinical study as proposed initially. In GLY group, four pa-
tients discontinued the study for the following reasons: one 
due to nausea and vomiting; one due to nausea, headache 
and dizziness; one due to nausea, sweating, asthenia and 
blurred vision; and one died with suspected histoplasmosis. 
Therefore in this group 20 patients completed the interven-
tion. Figure 1 provides a flow diagram of  the population 
selected for the study.
Baseline demographic and clinical characteristics of en-
rolled patients by intervention groups, age, gender, clinical 
classification of HIV infection according to the CDC(7), CD4, 
HIV viral load, antiretroviral usage, body mass index (BMI) 
and report of diarrhea in the last 14 days are summarized 
TABLE 1. Patients characteristics at baseline according to age, sex, clinical classification, CD4, HIV viral load, antiretroviral therapy, weight, body 
mass index and diarrhea in the last 14 days
Parameters
All Study groups
P
n = 46 Placebo GLY 
a
n = 24
AG b
n = 22
Age in years (Mean ± SE) 37.28 ± 3.00 40.13 ± 1.89 34.18 ± 1.66 0.024*
Gender
Male, n (%) 36 (78.3) 17 (70.8) 19 (86.4) NS
Female, n (%) 10 (21.7) 7 (29.2) 3 (13.6) NS 
Clinical classification c
A, n (%) 15 (32.6) 7 (29.2) 8 (36.4) NS
B, n (%) 3 (6.5) 1 (4.2) 2 (9.1) NS
C, n (%) 28 (60.9) 16 (66.6) 12 (54.5) NS
CD4/mm3, n (Mean ± SE) 44 (384.5 ± 16.47) 24 (409.5 ± 64.9) 20 (354.4 ± 46.0) NS
<200, n (%) 12 (27.3) 7 (29.2) 5 (25.0)) NS 
≥200, n (%) 32 (72.7) 17 (70.8) 15 (75.0) NS
VL (log
10
) , n (Mean ± SE) 37 (4.08 ± 1.05) 22 (4.08 ± 1.11) 15 (4.05 ± 0.99) NS
HAART
Yes, n (%) 38 (82.6) 22 (91.7) 16 (72.7) NS
No, n (%) 8 (17.4) 2 (8.3) 6 (27.3) NS
Weight, n (Median ± SE) 46 (60.9 ± 3.3) 24 (60.7 ± 2.4) 22 (62.2 ± 2.1) NS
BMI , n (Median ± SE) 46 (22.9 ± 1.9) 24 (22.3 ± 0.7) 22 (22.4 ± 0.8) NS
Diarrhea (last 14 days)
Yes, n (%) 9 (19.6) 6 (25.0) 3 (13.6) NS 
No, n (%) 37 (80.4) 18 (75.0) 19 (86.4) NS
a GLY = glycine (placebo) – GLY (25 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
b AG = alanyl-glutamine - AG (24 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
c CDC (1993)(7)
SE = standard error; NS = not significant; VL = HIV viral load; HAART = highly active antiretroviral therapy; BMI = body mass index
* P = 0.024 comparing the mean age between AG group and the GLY (placebo) group using the Student t test
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in Table 1. There were no significant statistical differences 
of  these parameters by treatment groups, except for age 
(40.13 ± 1.89 years in GLY group vs 34.18 ± 1.66 years in 
AG group; P = 0.024).
As shown in Table 2, at baseline there were no statisti-
cally significant differences in the intestinal permeability 
test between AG and GLY groups, nor according to use of 
antiretroviral therapy, CD4 count and the BMI. Among 
nine patients who had reported diarrhea in the last 14 days 
preceding the beginning of  the study the urinary excre-
tion of  mannitol was significantly lower [median (range): 
10.51 (3.01–19.75) vs 15.37 (3.93–46.73); P = 0.0281] and 
lactulose/mannitol ratio was significantly higher [median 
(range): 0.04 (0.00–2.89) vs 0.02 (0.00–0.19); P = 0.0317] 
when compared with patients who did not report diarrhea 
in this same period. 
There were no significant differences between AG and 
GLY groups in hemoglobin level, hematocrit, leukocyte and 
platelet count, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), urea and creatinine before and after 
the intervention proposed. There were also no significant 
differences in weight, BMI, HIV viral load, CD4, urinary 
excretion of lactulose and urinary lactulose/mannitol ratio 
between treatment groups (Table 3). Inversely, there was a 
TABLE 2. Intestinal permeability test parameters at baseline according to treatment groups, diarrhea occurrence in the last 14 days, use of HAART, 
CD4 and body mass index
Intestinal permeability test parameters
median (range) Treatment group or clinical status P
Placebo GLYa (n = 24) AG b (n = 22)
% of lactulose excretion 0.32 (0.00–8.71) 0.30 (0.00–3.82) NS
% of mannitol excretion 16.10 (3.01–46.70) 13.70 (5.30–31.60) NS
Lactulose/mannitol ratio 0.02 (0.00–2.89) 0.02 (0.00–0.19) NS
Diarrhea reported in the last 14 
days (n = 9)
No diarrhea reported in the last 
14 days (n = 36)
% of lactulose excretion 0.86 (0.00–8.71) 0.29 (0.00–3.82) 0.0318*
% of mannitol excretion 11.70 (3.01–22.20) 15.35 (3.90–46.70) NS
lactulose/mannitol ratio 0.05 (0.00–2.89) 0.02 (0.00–0.19) 0.0261*
Without HAART (n = 8) HAART use (n = 37)
% of lactulose excretion 0.33 (0.10–1.01) 0.29 (0.00–8.71) NS
% of mannitol excretion 17.05 (5.30–43.60) 14.00 (3.01–46.70) NS
Lactulose/mannitol ratio 0.03 (0.00–0.19) 0.02 (0.00–2.89) NS
CD4 <200/mm3 (n = 12) CD4 ≥200/mm3 (n = 31)
% of lactulose excretion 0.32 (0.00–1.38) 0.32 (0.00–8.71) NS
% of mannitol excretion 13.60 (6.40–46.70) 14.50 (3.01–43.60) NS
Lactulose/mannitol ratio 0.02 (0.00–0.22) 0.02 (0.00–2.89) NS
BMI <18.5 (n = 4) BMI ≥18.5 (n = 42)
% of lactulose excretion 0.67 (0.42–1.16) 0.29 (0.00–8.71) NS
% of mannitol excretion 12.50 (5.40–31.60) 14.50 (3.01–46.70) NS
lactulose/mannitol ratio 0.07 (0.01–0.13) 0.02 (0.00–2.89) NS
a GLY = Glycine (placebo) – GLY (25 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
b AG = alanyl-glutamine - AG (24 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
HAART = highly active antiretroviral therapy; NS = not significant; BMI = body mass index
* P = 0.0318 and P = 0.0261 comparing groups that reported and did not report diarrhea in the last 14 days at baseline, using the Student t test, for urinary excretion of lactulose (%) and for 
lactulose/mannitol ratio respectively
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significant increase in the percentage of  mannitol urinary 
excretion in the AG group [median (range)] after treatment: 
[14.38 (8.25–23.98) before treatment vs 21.24 (6.27–32.99) 
after treatment; n = 14, P = 0.0382], and no difference in 
GLY (placebo) group as shown in Table 3.
There were two SAE, one in each treatment group. In the 
AG group one patient was hospitalized as a result of head 
injury in a motorcycle accident. In the GLY group one patient 
died with suspected disseminated histoplasmosis. This patient 
was asymptomatic during his study treatment and when he 
presented at the 11th day to perform his intestinal absorption 
test he suddenly began to develop respiratory distress and 
was hospitalized and died after 4 days. AE do not differed 
significantly between treatment groups (Table 4).
TABLE 3. Changes in weight, BMI, CD4 count, viral load and intestinal permeability test after treatment with glycine (placebo) or alanyl-glutamine
Parameters Treatment groupPlacebo glycyne a Alanyl-glutamine b
Weight (kg) n = 20 P n = 17 P
Before (mean ± SE) 60.64 ± 2.59 NS 63.08 ± 2.04 NS 
After (mean ± SE) 62.66 ± 2.82 63.82 ± 1.98
BMI n = 20 n = 17
Before (mean ± SE) 23.75 ± 0.82 NS 22.62 ± 0.87 NS
After (mean ± SE) 23.73 ± 0.99 22.87 ± 0.86
CD4 (/mm3) n = 19 n = 17
Before (mean ± SE) 421.26 ± 75.84 NS 384.88 ± 48.48 NS 
After (mean ± SE) 278.45 ± 63.88 412.00 ± 54.97
HIV viral load (log
10
) n = 19 n = 9
Before (mean ± SE) 4.04 ± 0.56 NS 4.07 ± 0.99 NS 
After (mean ± SE) 3.86 ± 0.63 3.71 ± 0.72
% of lactulose excretion n = 19 n = 14
Before, median (range) 0.28 (0.00–1.15) NS 0.21 (0.00–3.82) NS 
After, median (range) 0.29 (0.00–3.95) 0.26 (0.00–1.17)
% of mannitol excretion n = 19 n = 14
Before, median (range) 16.79 (3.93–46.73) NS 14.38 (8.25–23.98) 0.0382*
After, median (range) 17.47 (0.00–47.51) 21.24 (6.27–32.99)
Lactulose/mannitol ratio n = 19 n = 14
Before, median (range) 0.02 (0.00–0.12) NS 0.02 (0.00–0.19) NS 
After, median (range) 0.02 (0.00–0.24) 0.01 (0.00–0.41)
a GLY = Glycine (placebo) – GLY (25 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
b AG = alanyl-glutamine - AG (24 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
BMI = body mass index; SE = standard error; NS = not significant
* P = 0.0382 comparing the percentage of mannitol urinary excretion before and after treatment in AG group, using paired Student t test
TABLE 4. Adverse events and serious adverse events according to treatment groups with alanyl-glutamine or glycine (placebo)
Parameters
Treatment groups
Placebo glycine a (n = 24) Alanyl-glutamine b (n = 22) Total (n = 46)
n % n % n %
Adverse event c
Dizziness 4 14.81 4 16.00 8 15.38
Nausea 4 14.81  4 16.00 8 15.38
Asthenia 2 7.40 2 8.00 4 7.69
Vomit 2 7.40 2 8.00 3 5.76
Facial paresthesia 2 7.40 0 0.00 2 3.84
Sweating 1 3.70 1 4.00 2 3.84
Cold extremities 1 3.70 1 4.00 2 3.84
Blurred vision 1 3.70 0 0.00 1 1.92
Headache 1 3.70 0 0.00 1 1.92
Constipation 1 3.70 0 0.00 1 1.92
Colic 1 3.70 0 0.00 1 1.92
Burning in thorax 1 3.70 0 0.00 1 1.92
Diarrhea 0 0.00 1 4.00 1 1.92
Fever 0 0.00 1 4.00 1 1.92
Paresthesia of members 0 0.00 1 4.00 1 1.92
Dyspnea 0 0.00 1 4.00 1 192
Serious adverse event d
Death e 1 3.70 0 0.00 1 1.92
Head injury f 0 0.00 1 4.00 1 1.92
a GLY = Glycine (placebo) – GLY (25 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
b AG = alanyl-glutamine - AG (24 g/day) was given with orange juice for 10 days, beginning on the 1st day of the study protocol
 c, d P >0.05 comparing treatment with versus GLY (Chi-square or Fisher’s exact test)
e Clinical feature of disseminated histoplasmosis
f Motorcycle accident
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DISCUSSION
Our study was proposed to evaluate the ability of  glu-
tamine on improving intestinal function of  HIV infected 
patients. For this purpose we have used AG, a dipeptide which 
physicochemical stability has been shown to be superior to 
the use of glutamine. In addition, glutamine hydrolysis tends 
to form glutamate, which is potentially toxic to the central 
nervous system. This problem does not happen with AG(10).
We observed that there was a significant difference in age 
between treatment groups, which was lower in AG group 
(34.18 versus 40.13 years; P = 0.024). This statistic, however, 
seems devoid of importance to influence the outcome of the 
study (Table 1).
Comparing intestinal permeability tests results in our 
study with the extremes of normality previously reported in 
healthy individuals in Brazil(32), 56.5%(19) of  our patients had 
greater urinary excretion of lactulose [0.32 (0.00-8.72) vs 0.07 
(0.05–0.28)], 60.9%(2) had lesser urinary excretion of mannitol 
[14.56 (3.02-124.11) vs 21 (18.30–28.00)], and 67.4%(25) had 
a greater lactulose/mannitol ratio [0.02 (0.00–2.89) vs 0.003 
(0.002–0.013)]. Soares et al.(28) had previously reported that in 
HIV/AIDS patients, with or without diarrhea or weight loss, 
D-xilose absorption test was abnormal when compared with 
healthy control subjects. In agreement with those findings, 
our data showed that most patients with HIV/AIDS still 
presents intestinal impaired absorption and altered perme-
ability, even in the era of HAART.
Diarrhea was reported as having occurred less than 14 
days before the baseline by nine (19.6%) patients (Table 1). 
As shown in Table 2, urinary mannitol excretion was signifi-
cantly lower [median (range): 10.51 (3.01–19.75) vs 15.37 
(3.93–46.73); P = 0.0281] and lactulose/mannitol ratio was 
significantly higher [median (range): 0.04 (0.00–2.89) vs 0.02 
(0.00–0.19); P = 0.0317] in this group than among patients 
who did not report diarrhea. This result is similar to the data 
previously reported by Lima et al.(15) published before the ad-
vent of HAART. The advantage of an intestinal absorption 
test that uses two sugars with distinct molecular sizes is to 
make possible to evaluate at the same time intestinal lesion 
(increased urinary excretion of lactulose) and a change in 
intestinal absorption surface (reduced excretion of manni-
tol), as reported by Sorensen et al.(29). Our data shows the 
impact of diarrhea in intestinal absorption in patients with 
HIV/AIDS, mainly suggesting the reduction of  intestinal 
absorption surface.
Potentially less favorable clinical conditions such as CD4 
lower than 200/mm3, BMI lower than 18.5 and being in use of 
antiretroviral therapy (Table 2) did not represent conditions 
that significantly altered intestinal permeability tests at base-
line. Perhaps this could be explained because the majority 
of patients were already on HAART or it might have been 
necessary the inclusion of a greater number of patients to 
find differences between those groups.
We choose GLY as placebo. GLY did not interfere in the 
treatment of  diarrhea when added to an oral rehydration 
solution in a previous study(31). Additionally, the use of GLY 
has made possible providing the required equal amount of 
nitrogen for the two treatment groups.
There are increasing evidences that glutamine may act as 
a vital signaling molecule to the cells in the event of illness 
or trauma, able to play a regulatory role of  several genes 
associated with metabolism, signal transduction, cell repair 
and defense and also to signalize activation of intracellular 
pathways(8). It is therefore possible that the release of gluta-
mine by muscle or other tissues acts as a “stress signaling” 
to the body to the activation of vital genes for cell protection 
and immune regulation(34).
During catabolism states a large amount of  amino ac-
ids, including glutamine, is released from the muscle tissue. 
Therefore, it is expected that, as in critical patients that has 
evidenced low serum levels of glutamine, the same occurs in 
patients living with HIV/AIDS(22, 24). So, it is reasonable to as-
sume that dietary supplementation with glutamine may have 
a positive impact on the nutritional status of these patients. 
As can be seen in Table 3 there were no significant changes 
in anthropometric parameters in the group that received 
AG, neither in the group that received GLY. This could be 
explained because we did not make subsequent anthropomet-
ric evaluations and by the short period of treatment used in 
our protocol. Shabert et al.(26), using a different study design 
from ours and in which treatment with glutamine (40 g/day) 
for HIV infected patients continued for 3 months, observed 
2.2 kg of median weight gain, 1 kg of body cell mass gain 
and an increase of intracellular water.
One of the striking features of the immune system is the 
high rate of consumption of glutamine by its cells in culture 
media(18). Hack et al.(13), for instance, described a strong as-
sociation between the fall in serum levels of glutamine and 
the decrease of  T CD4+ lymphocytes (r = 0.67, P<0.001) 
of  a group of  individuals after 8 weeks of  a program of 
physical exercises. On his turn, Jing-Xiang et al.(14) observed 
a significant increase in the count of T CD4+ lymphocytes 
and also of CD4/CD8 ratio on the 4th post-operative day 
of a group of patients with colorectal cancer who received 
parenteral nutrition enriched with AG. In AG group of our 
trial there was an increase in the absolute count and in the 
percentage of T CD4+ lymphocytes. Inversely, in GLY group 
we observed a reduction in these parameters after 10 days 
of treatment (Table 3). However, those differences were not 
statistically significant. In the light of recent concepts about 
the importance of maintaining the integrity of the mucosal 
barrier to inhibit microbial translocation and thus prevent 
the systemic immune activation and consequent depletion of 
T CD4+ cells(3), our result of increase in the absolute count 
and percentage of T CD4+ lymphocytes in the AG group is 
particularly exciting about a possible role of  glutamine in 
preservation and repair of intestinal mucosa.
No significant changes in urinary lactulose excretion and 
on lactulose/mannitol ratio were observed in either treatment 
group (Table 3). However, there was a significant increase in 
urinary excretion of mannitol in AG group [median (range): 
14.38 (8.25–23.98) before vs 21.24 (6.27–32.99) after treat-
ment; P = 0.0382] as shown in Table 3. These results may 
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suggest that the initial effect of AG in HIV infected patients 
seems to be the recovery of intestinal absorptive area and, 
subsequently, the repair of the intestinal barrier lesion. In 
agreement with our findings, Noyer et al.(19) have conducted 
a study in which a group of  patients received glutamine 
(8 g/day) during 28 days and also presented an increase in 
urinary excretion of mannitol, although not significant. In 
another clinical trial, the group of patients randomized to 
receive higher doses of AG and glutamine for 1 week also 
showed a tendency to have an increase in the urinary excre-
tion of mannitol, although not significant. Also in this study 
there has been no significant change in the urinary excretion 
of lactulose(5). Taken together, these results may suggest that 
both the dose of  AG or glutamine used as the treatment 
duration are important in order to achieve an effect on the 
absorption and on rupture repair of  intestinal barrier in 
patients with HIV/AIDS. Our result is also consistent with 
the observations of Batman et al.(2), who suggest that the cell 
hyperplasia of crypts could represent the primary lesion of 
HIV enteropathy, determining the migration of  immature 
enterocytes into the villi and, thus, leading to a reduction of 
the intestinal absorption area by mobilizing the villi from the 
crypt-villi junction toward the lumen.
Considering the relative scarcity of studies dealing with 
glutamine supplementation safety(32) we established a con-
trol system for AE and SAE in our clinical trial. The most 
common AE were dizziness and nausea, with no significant 
differences between the treatment and placebo (glycine) 
groups (Table 4). All AE resolved without sequel and neither 
one of the two SAE was definitively linked with either of the 
two treatments.
Recent studies of  HIV and simian immunodeficiency 
virus (SIV) infections have shown a decrease in the expres-
sion of genes associated with repair and regeneration of the 
intestinal mucosa, including several factors of  cell growth 
and proliferation(11, 12, 25). Those studies suggest that the 
processes of inflammation and regeneration of the mucosa 
may be object of modulation through the development of 
new drugs able to stimulate the restoration of the intestinal 
mucosal immune system and the repair of the GALT. Curi et 
al.(8) suggested that glutamine has a regulatory role of several 
genes related to metabolism, to signaling transduction, to 
cell defense and to repairing and activating of intracellular 
pathways signaling. Thus, pharmacogenomics studies with 
this amino acid seem to be more than ever on the agenda.
In conclusion, in agreement with others(6, 17, 27), we observed 
that diarrhea remains a clinical problem among patients with 
HIV/AIDS, even among those taking HAART, and that 
diarrhea has a significant impact on intestinal permeability. 
Additionally, AG was safe and able to produce an effect of 
improvement in intestinal absorption area in HIV infected 
patients, as suggested by the finding of a significant increase 
in the percentage of urinary excretion of mannitol, and thus 
deserves further study in ameliorating the diarrhea and malab-
sorption that remains a problem for patients with HIV/AIDS.
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RESUMO - Contexto - A glutamina é a principal fonte de energia do enterócito e diarreia e perda de peso são frequentes em pacientes infectados pelo 
HIV. Objetivo - Determinar o efeito da alanil-glutamina sobre a permeabilidade e a absorção intestinais nesses pacientes. Métodos - Estudo duplo-ce-
go, randomizado, controlado por placebo, utilizando doses isonitrogênicas de alanil-glutamina (24 g/dia) e de placebo (glicina, 25 g/dia) durante 10 
dias. Antes e depois dessa suplementação nutricional a excreção urinária de lactulose e manitol foi determinada por cromatografia líquida de alta 
performance. Resultados - Quarenta e seis pacientes com HIV/AIDS, sendo 36 do sexo masculino, com 37,28 ± 3 anos (média ± erro padrão) foram 
incluídos. Vinte e dois e 24 indivíduos foram tratados com alanil-glutamina e com glicina, respectivamente. Nos nove pacientes que relataram ter 
apresentado diarreia nos 14 dias anteriores ao início do estudo, a excreção urinária de manitol foi significativamente menor do que nos pacientes 
que não referiram essa queixa [mediana (intervalo): 10,51 (3,01-19,75) vs 15,37 (3,93-46,73), P = 0,0281] e a razão lactulose/manitol foi significativa-
mente mais elevada [mediana (intervalo): 0,04 (0,00-2,89) vs 0,02 (0,00-0,19), P = 0,0317]. Constatou-se também aumento significativo na excreção 
urinária de manitol no grupo tratado com alanil-glutamina [mediana (intervalo): 14,38 (8,25-23,98), antes vs 21,24 (6,27-32,99) após o tratamento, 
n = 14, P = 0,0382]. Conclusão - Os resultados do presente estudo sugerem que a integridade e a absorção intestinais são mais intensamente afetadas 
em pacientes com HIV/AIDS que tiveram diarreia recentemente. Adicionalmente, a suplementação nutricional com alanil-glutamina associou-se à 
melhoria na absorção intestinal.
DESCRITORES – Absorção intestinal. Glutamina. HIV. Placebo.
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